Compare Amylx Pharmaceuticals Inc (AMLX) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Symbotic Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.28 (market cap $1.98B), while Symbotic Inc trades at $42.88 (market cap $5.55B). The key difference: Symbotic Inc is far larger — about 2.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | SYM | |
|---|---|---|
Market Cap | $1.98B | $5.55B |
Sector | Health | Technology |
52-Week High | $18.70 | $87.30 |
52-Week Low | $7.64 | $38.57 |
Enterprise Value | $1.70B | $3.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SYM trades at $43.64, up 1.14% with neutral technical signals. The company reported $2.25B revenue in 2025 but a net loss of $16.94M, though margins are improving. Recent acquisition of ARMS Innovations expands warehouse automation capabilities. Analyst consensus is bullish with a $57.50 price target, representing 32% upside potential from current levels.
Outlook remains positive due to strong revenue growth and expanding automation market, but profitability challenges and competitive pressures present risks. The stock offers growth potential but requires monitoring of earnings trajectory and market position in the evolving robotics sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
